ANCEF
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANCEF is a small-molecule injectable antibiotic approved in 1973 by GSK. The generic name is not specified in available data, but it is indicated for bacterial infections requiring parenteral therapy. It represents a mature, well-established injectable treatment modality.
LOE Approaching
With LOE approaching and moderate competitive pressure (30), expect declining commercial team size and shift from growth to defense and transition-planning initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ANCEF offers limited career growth opportunities given its LOE-approaching status and zero linked job postings. Roles focus on defending market share, managing generic transition, and cost containment rather than innovation.
Brand ManagerSales Representative
Worked on ANCEF at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.